Drug Search Results
Using advanced filters...
Advanced Search [+]

house dust mites

Alternative Names: house dust mites
Clinical Status: Inactive
Latest Update: 2025-05-19
Latest Update Note: News Article

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Nondrug

Route of Administration: Oral,Sublingual

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Canada | Czech | Denmark | Finland | Germany | Greece | Hungary | Iceland | Ireland | Israel | Korea | Luxembourg | Netherlands | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Sweden | Switzerland | Turkey | Ukraine | United States

Approved Indications: None

Known Adverse Events: None

Company: Probelte Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for house dust mites

Countries in Clinic: Spain

Active Clinical Trial Count: 3

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Asthma, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic

Phase 2: Conjunctivitis, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

TiME (short allergen immunotherapy mites)

P2

Completed

Rhinitis, Allergic|Asthma, Allergic|Conjunctivitis, Allergic

2023-02-04

2025-06-30

Treatments

PROACAROS

P3

Recruiting

Dust mite Hypersensitivity|Environmental Hypersensitivity

2026-06-01

31%

2024-07-19

Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

2018-003427-11

P3

Active, not recruiting

Rhinitis, Allergic|Asthma, Allergic

2023-10-07

2025-06-17

Treatments